Kevin Lee - Jan 3, 2023 Form 4 Insider Report for BICYCLE THERAPEUTICS plc (BCYC)

Role
Chief Executive Officer, Director
Signature
/s/ Lee Kalowski, Attorney-in-Fact
Stock symbol
BCYC
Transactions as of
Jan 3, 2023
Transactions value $
-$174,360
Form type
4
Date filed
1/5/2023, 08:06 PM
Previous filing
Jan 5, 2022
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCYC Ordinary Shares Award $0 +57.5K +20.9% $0.00 333K Jan 3, 2023 Direct F1, F2
transaction BCYC Ordinary Shares Sale -$174K -6K -1.8% $29.06 327K Jan 3, 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCYC Employee Stock Option (right to buy) Award $0 +115K $0.00 115K Jan 3, 2023 Ordinary Shares 115K $29.60 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2 Each RSU represents a contingent right to receive one ordinary share.
F3 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter.